Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Targeted Search
Clinical Trials Search Results
Query: "AREA[SponsorSearch](Tonix Pharmaceuticals, Inc.)"
Count: 29
Selected: 0
| NCT ID | Title |
|---|
| NCT05686408 | Study to Evaluate TNX-601 ER Monotherapy Versus Placebo in Patients With Major Depressive Disorder (MDD) | ||
| NCT05679908 | A Study to Evaluate the Efficacy and Safety of TNX-1900 in Patients With Chronic Migraine | ||
| NCT05472090 | A Phase 2 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Patients With Multi-Site Pain Associated With Post-Acute Sequelae of SARS-CoV-2 Infection | ||
| NCT05372887 | Safety and Efficacy Study of TNX-102 SL in Participants With PTSD | ||
| NCT05273749 | A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily in Patients With Fibromyalgia | ||
| NCT05216510 | Assessment of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 Peptide Antigens | ||
| NCT04996056 | An Open-Label, Randomized Pilot Study Comparing the Safety of a Single Dose of TNX-1300 to Usual Care (UC) Alone for the Treatment of Signs and Symptoms of Acute Cocaine Intoxication in Male Emergency Department (ED) Subjects | ||
| NCT04508621 | A Phase 3 Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia | ||
| NCT04172831 | A Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia | ||
| NCT04164719 | Dose-Proportionality and Food Effect Study of TNX-102 SL | ||
| NCT03841773 | A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Participants With PTSD | ||
| NCT03508700 | A 40-week Study to Evaluate TNX-102 SL 5.6 mg Taken Daily at Bedtime in Patients With PTSD | ||
| NCT03443960 | Steady-State Pharmacokinetic Comparison Study of TNX-102 SL 5.6 mg Versus AMRIX® 30 mg ER Capsules | ||
| NCT03168022 | Bioequivalence Study of TNX-102 SL 2.8 mg Sublingual Tablets From Two Manufacturers. | ||
| NCT03110575 | 12-Week Open-Label Extension Study of TNX-102 SL in PTSD Patients | ||
| NCT03062540 | Safety and Efficacy Study of TNX-102 SL in Patients With Military-related PTSD | ||
| NCT02829814 | Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia | ||
| NCT02589275 | A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients | ||
| NCT02436096 | A Study to Evaluate eFFIcacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With fibRoMyalgia | ||
| NCT02423408 | Safety and Efficacy Study of TNX-201 Capsules for Treatment of Single Tension-Type Headache | ||
| NCT02421679 | Open Label Extension Safety and Efficacy Study of TNX-102 SL Tablets in Military Related PTSD and Related Conditions | ||
| NCT02290379 | Phase 1 Single Ascending Dose Safety Study of TNX-201 Capsules in Healthy Volunteers | ||
| NCT02277704 | Safety and Efficacy Study of TNX-102 SL in Subjects With Military-Related PTSD and Related Conditions | ||
| NCT02015234 | 12-Month Open-Label Long-term Safety Study of TNX-102 SL Tablets in Fibromyalgia Patients | ||
| NCT01903265 | BEdtime Sublingual TNX-102 SL as Fibromyalgia Intervention Therapy (BESTFIT) | ||
| NCT01889173 | Comparative Pharmacokinetics and Safety of 3 Different Formulations of TNX-102 2.8 mg SL Tablets and Cyclobenzaprine 5 mg Oral Tablet in Healthy Adults | ||
| NCT01689259 | Comparative Pharmacokinetics and Safety of TNX-102 SL Tablets and Cyclobenzaprine Oral Tablet in Healthy Adults | ||
| NCT01634412 | Comparative Bioavailability of Sublingual TNX-102, Oral and Intravenous Cyclobenzaprine in Healthy Adults | ||
| NCT01490788 | A Comparative Bioavailability and Pharmacokinetic Study of TNX-102 2.4 mg and Cyclobenzaprine 5 mg Tablets in Healthy Adults. |
